# A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

Source: https://onco.cc/trials/nct07849231/  
OnCo record `nct07849231` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DMR-001 run by Damora Therapeutics, now recruiting.

## Summary

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms is a phase 1 interventional study registered as NCT07849231 by Damora Therapeutics, with 250 participants planned, started 2026-09. Conditions recorded: Myeloproliferative Neoplasms (MPNs). Interventions recorded: DMR-001 and Ruxolitinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07849231
- Phase: 1
- Setting: A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies, Administered Alone or in Combination With Ruxolitinib, in Participants With CALR-mutant Myeloproliferative Neoplasms
- Sponsor: Damora Therapeutics
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT07849231: https://clinicaltrials.gov/study/NCT07849231

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [DMR-001](https://onco.cc/drugs/dmr-001/)
- companies: [Damora Therapeutics](https://onco.cc/companies/damora-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07849231.json